>> The Company is in the development stage and has only engaged in organizational and fundraising activities to date. Its principal asset is the exclusive license with Argyll Biotech. The Company intends to develop its operations so that it is in a position to market, distribute and sell SF-1019 as soon as appropriate regulatory approvals are received by Argyll Biotech for SF-1019. <<
Why is there a need to develop a marketing and distribution infrastructure for a drug that is a probably a decade away from being approved for marketing? Something here doesn’t compute.